Medical treatment of neuroendocrine tumours

Area of Science:

• Oncology
• Medical Research

Background:

• Neuroendocrine tumors (NETs), including pancreatic NETs (PNETs), often present at advanced stages.
• While surgery can be curative, medical therapies are crucial for advanced NETs.
• The prevalence of NETs has increased in recent decades.

Purpose of the Study:

• To review recent clinical trials on treating advanced neuroendocrine tumors (NETs) and pancreatic NETs (PNETs).
• To summarize therapeutic advancements targeting key molecular pathways in NETs.

Main Methods:

• Review of recent randomized clinical treatment trials.
• Analysis of therapies targeting the mammalian target of rapamycin (mTOR) signaling pathway.
• Evaluation of treatments involving various tyrosine kinases and somatostatin analogues.

Main Results:

• Somatostatin analogues, mTOR inhibitors, and tyrosine kinase inhibitors demonstrated improved progression-free survival in well-differentiated midgut NETs.
• Everolimus, an mTOR inhibitor, effectively reduced peptide secretion in functional PNETs, alleviating clinical symptoms.
• Targeting mTOR and tyrosine kinase pathways has shown encouraging results in managing advanced NETs.

Conclusions:

• Molecular pathology of NETs highlights mTOR and tyrosine kinase signaling as critical therapeutic targets.
• Recent clinical trials confirm the efficacy of inhibitor therapies targeting these pathways.
• These targeted therapies offer prolonged progression-free survival and improved management of secretion-related syndromes in NET patients.